SLC-3010

N/A

Report date: 2026/03/16 20:01:47

Base Information

Drug NameSLC-3010
Drug Alias NameSLC-3010
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionInterleukin-2 receptor agonists
TargetsInterleukin-2 receptor
Therapy Area/IndicationsSolid tumoursKidney NeoplasmsCarcinoma, Renal Cell +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaSouth Korea
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSelecxine Inc
China Registration ClassN/A

Develop Information

Active CompaniesSelecxine IncYonsei University
Inactive CompaniesN/A
Active IndicationsSolid tumoursKidney NeoplasmsCarcinoma, Renal Cell +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A